Clinical Trial

To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-28; most recent amendment 2026-01-22.
Status change: Not Yet Recruiting → Recruiting 2025-08-03
Trial Details
NCT Number NCT07090759
Lead Sponsor Fujian Akeylink Biotechnology Co., Ltd.
Conditions Chronic Hepatitis b
Enrollment 526 participants
Start Date 2025-07-24
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-23